Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Shomura, Masako ^a,d   Kagawa, Tatehiro ^b   Okabe, Haruka ^a   Shiraishi, Koichi ^b   Hirose, Shunji ^b   Arase, Yoshitaka ^b   Tsuruya, Kota ^b   Takahira, Sachiko ^c   Mine, Tetsuya ^b  

^a TOKAI UNIVERSITY   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF NAGASAKI   (Japan)

^d NONE   (Japan)

Author keywords

Advanced hepatocellular carcinoma; Clinical course; Health related quality of life; Prognostic marker; Sorafenib

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADULT; ADVANCED CANCER; AGE; AGED; ANOREXIA; ARTICLE; BODY WEIGHT DISORDER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHILD PUGH SCORE; COMORBIDITY; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT HISTORY OF THERAPY; PROSPECTIVE STUDY; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; SEX DIFFERENCE; SHORT FORM 36; SKIN TOXICITY; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; KAPLAN MEIER METHOD; LIVER NEOPLASMS; LONGITUDINAL STUDY; MIDDLE AGED; MORTALITY; PATHOLOGY; SOCIAL BEHAVIOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

EID: 84995468843     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2908-7     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90. doi: 10.3322/caac.20107.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34. doi: 10.1016/s1470-2045(08)70285-7.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, SHARP Investigators Study Group, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90. doi: 10.1056/NEJMoa0708857.
4. Dancey J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res. 1997;6:151-8.
5. Braun DP, Gupta D, Staren ED. Quality of life assessment as a predictor of survival in non-small cell lung cancer. BMC Cancer. 2011;11:353. doi: 10.1186/1471-2407-11-353.
6. Braun DP, Gupta D, Grutsch JF, Staren ED. Can changes in health related quality of life scores predict survival in stages III and IV colorectal cancer? Health Qual Life Outcomes. 2011;9:62. doi: 10.1186/1477-7525-9-62.
7. Steel JL, Geller DA, Robinson TL, Savkova AY, Brower DS, Marsh JW, et al. Health-related quality of life as a prognostic factor in patients with advanced cancer. Cancer. 2014;120:3717-21. doi: 10.1002/cncr.28902.
8. Grunwald V, Soltau J, Ivanyi P, Rentschler J, Reuter C, Drevs J. Molecular targeted therapies for solid tumors: management of side effects. Onkologie. 2009;32:129-38. doi: 10.1159/000194949.
9. Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Takenaka A, Inoue TA, et al. Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation. BJU Int. 2010;106:1643-7. doi: 10.1111/j.1464-410X.2010.09437.x.
10. Trask PC, Bushmakin AG, Cappelleri JC, Bycott P, Liau K, Kim S. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib. Acta Oncol. 2008;47:843-51. doi: 10.1080/02841860802047395.
11. Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, et al. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015;51:833-40. doi: 10.1016/j.ejca.2015.03.004.
12. Nardone B, Hensley JR, Kulik L, West DP, Mulcahy M, Rademaker A, et al. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol. 2012;11:e61-5.
13. Brunocilla PR, Brunello F, Carucci P, Gaia S, Rolle E, Cantamessa A, et al. Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol. 2013;30:345. doi: 10.1007/s12032-012-0345-2.
14. Boursier J, Cesbron E, Tropet AL, Pilette C. Comparison and improvement of MELD and Child-Pugh score accuracies for the prediction of 6-month mortality in cirrhotic patients. J Clin Gastroenterol. 2009;43:580-5. doi: 10.1097/MCG.0b013e3181889468.
15. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:909-22. doi: 10.1097/01.sla.0000254368.65878.da.
16. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55.
17. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 health survey for use in Japan. J Clin Epidemiol. 1998;51:1037-44.
18. Fukuhara S, Ware Jr JE, Kosinski M, Wada S, Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 health survey. J Clin Epidemiol. 1998;51:1045-53.
19. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60. doi: 10.1055/s-0030-1247132.
20. Japan Clinical Oncology Group. Common Terminology Criteria for Adverse Events (CTCAE) v4.0-Japan Clinical Oncology Group. 2009. Available at http://www.jcog.jp/doctor/tool/CTCAEv4J_20160310.pdf. Accessed 25 Mar 2016.
21. Bukowski R, Cella D, Gondek K, Escudier B. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol. 2007;30:220-7. doi: 10.1097/01.coc.0000258732.80710.05.
22. Koldenhof JJ, Witteveen PO, de Vos R, Walraven M, Tillier CN, Verheul HM, et al. Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions. Support Care Cancer. 2014;22:2371-80. doi: 10.1007/s00520-014-2223-2.
23. Shomura M, Kagawa T, Shiraishi K, Hirose S, Arase Y, Koizumi J, et al. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol. 2014;6:670-6. doi: 10.4254/wjh.v6.i9.670.
24. Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol. 2007;36:319-24. doi: 10.1097/COC.0b013e3182468039.
25. Koschny R, Gotthardt D, Koehler C, Jaeger D, Stremmel W, Ganten TM. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology. 2013;84:6-13. doi: 10.1159/000342425.
26. Yeo W, Mo FK, Koh J, Chan AT, Leung T, Hui P, et al. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol. 2006;17:1083-9. doi: 10.1093/annonc/mdl065.
27. Diouf M, Filleron T, Barbare JC, Fin L, Picard C, Bouché O, et al. The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol. 2013;58:509-21. doi: 10.1016/j.jhep.2012.11.019.
28. Behrens G, Matthews CE, Moore SC, Freedman ND, McGlynn KA, Everhart JE, et al. The association between frequency of vigorous physical activity and hepatobiliary cancers in the NIH-AARP Diet and Health Study. Eur J Epidemiol. 2013;28:55-66. doi: 10.1007/s10654-013-9767-1.
29. Ukawa S, Tamakoshi A, Wakai K, Kurozawa Y. Associations of daily walking and television viewing time with liver cancer mortality: findings from the Japan Collaborative Cohort Study. Cancer Causes Control. 2014;25:787-93. doi: 10.1007/s10552-014-0380-8.
30. Cron DC, Friedman JF, Winder GS, Thelen AE, Derck JE, Fakhoury JW, et al. Depression and frailty in patients with end-stage liver disease referred for transplant evaluation. Am J Transplant. 2016;16:1805-11. doi: 10.1111/ajt.13639.
31. Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant. 2014;14:1870-9. doi: 10.1111/ajt.12762.
32. Chang SF, Lin PL. Frail phenotype and mortality prediction: a systematic review and meta-analysis of prospective cohort studies. Int J Nurs Stud. 2015;52:1362-74. doi: 10.1016/j.ijnurstu.2015.04.005.
33. Gill TM, Gahbauer EA, Han L, Allore HG. Trajectories of disability in the last year of life. N Engl J Med. 2010;362:1173-80. doi: 10.1056/NEJMoa0909087.
34. Sinn DH, Cho JY, Gwak GY, Paik YH, Choi MS, Lee JH, et al. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS One. 2015;10, e0124434. doi: 10.1371/journal.pone.0124434.
35. Miyahara K, Nouso K, Morimoto Y, Tomoda T, Kobayashi S, Takeuchi Y, et al. Evaluation of the effect of sorafenib using serum NX-des-γ-carboxyprothrombin in patients with hepatocellular carcinoma. Hepatol Res. 2013;43:1064-70.
36. Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, et al. Development and validation of a new prognostic system for patients with hepatocellular carcinoma. PLoS Med. 2016;13, e1002006. doi: 10.1371/journal.pmed.1002006.
37. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;31(379):1245-55. doi: 10.1016/S0140-6736(11)61347-0.
38. Montella L, Addeo R, Cennamo G, Vincenzi B, Palmieri R, Sperlongano P, et al. Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series. Oncology. 2013;84:265-72. doi: 10.1159/000345558.